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Abstract 
Purpose: To study the structure-activity relationships of synthetic multifunctional sulfides through 
evaluation of lipoxygenase and anti-bacterial activities. 
Methods: S-substituted derivatives of the parent compound 5-(1-(4-chlorophenylsulfonyl) piperidin-3-
yl)-1, 3, 4-oxadiazole-2-thiol were synthesized through reaction with different saturated and unsaturated 
alkyl halides in DMF medium, with NaH catalyst. Spectral characterization of each derivative was 
carried out with respect to IR, 1H - NMR, 13C - NMR and EI - MS. The lipoxygenase inhibitory and 
antibacterial activities of the derivatives were determined using standard procedures. 
Results: Compound 5e exhibited higher lipoxygenase inhibitory potential than the standard 
(Baicalein®), with % inhibition of 94.71 ± 0.45 and IC50 of 20.72 ± 0.34 µmoles/L. Compound 5b showed 
significant antibacterial potential against all the bacterial strains with % inhibition ranging from 62.04 ± 
2.78, 69.49 ± 0.41, 63.38 ± 1.97 and 59.70 ± 3.70 to 78.32 ± 0.41, while MIC ranged from 8.18 ± 2.00, 
10.60 ± 1.83, 10.84 ± 3.00, 9.81 ± 1.86 and 11.73 ± 5.00 µmoles/L for S. typhi, E. coli, P. aeruginosa, B. 
subtilis and S. aureus, respectively. Compounds 5d, 5e and 5g showed good antibacterial activity 
against S. typhi and B. subtilis bacterial strains. 
Conclusion: The results suggest that compound 5e bearing n-pentyl group is a potent lipoxygenase 
inhibitor, while compound 5b with n-propyl substitution is a strong antibacterial agent. In addition, 
compounds 5d, 5e and 5g bearing n-butyl, n-pentyl and n-octyl groups, respectively, are good 
antibacterial agents against S. typhi and B. subtilis. 
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Millions of people suffer from bacterial infectious 
diseases which are among the leading causes of 
morbidity and mortality worldwide [1,2]. Thus 
infectious diseases of bacterial aetiology are of 
serious public health significance. However, the 
treatment and management of bacterial 
infectious diseases are hampered by numerous 
factors, including the emergence of multi-drug 
resistant strains of bacteria [3]. The phenomenon 
of multi-drug resistance has led to increasing 
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attention on the search for new, synthetic 
compounds with potential anti-microbial 
properties. Indeed a large number of compounds 
have been synthesized and evaluated for their 
anti-microbial potential [4,5]. 
 
Oxadiazole compounds have potent 
pharmacological properties. They are 5-
membered heteroaromatic rings which exist in 
different isomeric forms. Oxadiazoles have been 
characterized as frequently occurring motifs in 
drug-like compounds [6]. The 2,5-di-substituted -
1, 3 4- oxadiazoles associated with a wide range 
of hetero-atom rings are important parts of a 
variety of clinical drugs used for management of 
different diseases. 
 
Oxadiazole-derived compounds have a wide 
range of medical applications such as anti-
tussive, anaesthetic, anti-inflammatory, anti-
allergic, vasodilator and anti-helmintic [7] 2, 5-di-
substituted-1, 3, 4-oxadiazoles are known to 
have fungicidal [3], anti-inflammatory [4,5], 
antitumor [8], insecticidal, herbicidal, antiviral, 
analgesic [9], antibacterial [10], anti-tubercular 
[11], herbicidal, anti-malarial, anti-convulsant and 
cytotoxic [12-14] activities. The present study 
was aimed at synthesizing S-substituted 
derivatives of 5-(1-(4–chlorophenysulfonyl) 
piperidin-3-yl)-1,3,4-oxadiazole-2-thiol, and 
investigating the lipoxygenase inhibitory and 






All chemicals were products of either Merck 
(Darmstadt) or Sigma Aldrich (St Louis). For 
column chromatography (CC), silica gel (70 - 230 
mesh) was used. Silica plates (0.25 mm) coated 
on alumina were used for thin layer 
chromatography (TLC) to check the purity of 
synthesized compounds. Ethyl acetate:n-hexane 
(30:70) was used as mobile phase. To visualize 
the fluorescent spots UV lamp was utilized at 254 
nm. Using KBr pellet method Jasco FTIR 
spectrometer recorded the IR spectra. Bruker 
spectrometers working at 300 and 400 MHz were 
employed in recording the 1H-NMR and 13C-NMR 
spectra. CDCl3 was used as solvent and TMS 
was the reference standard. Chemical shifts (δ) 
were given in ppm, while coupling constants (J) 
were recorded in Hz. EIMS spectra were 
recorded on JMS-HX 110 spectrometer. Melting 
points were determined on Griffin and George 
melting point apparatus using open capillary tube 
method. 
 
Synthesis of Ethyl-1-[(4-chlorophenyl) 
sulfonyl] piperidine-3-carboxylate (1) 
 
Ethyl piperidine-3-carboxylate (a) (30 mmol) 
(Scheme 1) was mixed with 4-chlorobenzene 
sulfonyl chloride (30 mmol) in 30 mL distilled 
water contained in 100 mL round bottom flask. 
During the reaction, the pH of reaction medium 
was maintained at 10 - 11 by addition of a small 
amount of 15 % Na2CO3 solution and the 
reaction mixture was stirred at room temperature. 
TLC was utilized for monitoring reaction 
progress, with n-hexane and EtOAc as mobile 
phase. At the end of the reaction, the flask 
contents were neutralized and precipitates were 
filtered, washed with distilled water and re-
crystallized in ethanol. The resultant crystalline 
product was designated as compound 1. 
 
Synthesis of 1-[(4-chlorophenyl) sulfonyl] 
piperidine-3-carbohydrazide (2) 
 
Compound 1 (25 mmol) was refluxed with 80 % 
hydrazine hydrate  (40 mmol) in 50 mL methanol 
contained in 100 mL round bottom flask for 2 - 3 
h. Reaction was monitored by TLC and on 
completion of the reaction, excess methanol was 
distilled off. Cold distilled water was introduced to 
the reaction mixture and the precipitates were 
filtered, washed with water and recrystallized 




piperidinyl)-1, 3, 4-oxadiazole-2-thiol (3) 
 
Compound 2 (65 mmol) was dissolved in 60 mL 
ethanol along with CS2 (65 mmol) and KOH (0.13 
mol) in 100 mL round bottom flask. KOH was 
used to provide an alkaline environment to 
enhance the electrophilicity of CS2. The reaction 
mixture was refluxed for 5 h and reaction 
progress was monitored with TLC. Excess 
ethanol was distilled off at the completion of 
reaction. The reaction contents were dissolved in 
distilled water and acidified to obtain the 
oxadiazole precipitates. The precipitates were 
filtered and washed with distilled water to yield 
compound 3. 
 
Synthesis of S-substituted derivatives of 5-{1-
[(4-chlorophenyl) sulfonyl]-3-piperidinyl}-1, 3, 
4-oxadiazol-2-yl sulfide 
 
Compound 3 (1 mmol) was taken in 50 mL round 
bottom flask along with 7 - 10 mL of DMF. 
Equimolar NaH was introduced to the reaction 
flask and the contents were stirred for 30 min at 
room temperature.  
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Scheme-1: Outline for the synthesis of S-substituted derivatives of 5-(1-(4-chlorophenylsulfonyl) piperidin-3-yl)-1, 
3, 4-oxadiazole-2-thiol 
 





























































Different saturated/unsaturated alkyl halides (1 
mmol) were added separately to the reaction 
mixture in the round bottom flask and the mixture 
was stirred for 4 h. At the end of reaction, cold 
distilled water was added and the precipitates 
were washed thoroughly with water. Seven 
different S-substituted derivatives resulted from 
the different alkyl halides (Table 1). 
 




The antibacterial activity of each S-substituted 
alkyl derivative was evaluated using the methods 
of Kaspady et al [15] and Yang et al [16]. Two 
gram-positive bacteria (Bacillus subtilis and 
Staphylococcus aureus), and three gram-
negative bacteria (Escherichia coli, 
Pseudomonas aeruginosa and Salmonella typhi) 
were clinically isolated and stored on appropriate 
agar media to facilitate bacterial growth. All the 
strains were obtained from a local hospital. Test 
samples (20 µg), after suitable dilution was 
added to 180 µL of diluted fresh bacterial 
cultures in nutrient broth in a microplate. The 
initial absorbance at 540 nm was taken and kept 
at values between 0.12 - 0.19. CiprofloxacinR 
was used as standard drug. The microplates with 
lids were incubated at 37 oC for 16 - 24 h. 
Absorbance was read at 540 nm in a microplate 
reader, before and after incubation and the 
difference was used as an index of bacterial 
growth. Percent inhibition was calculated as in 
Eq 1. 
 
Inhibition (%) = {(C – T)/C}100 ……………… (1)                               
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where C (i.e., control) = total enzyme activity 
without inhibitor, and T (i.e., test sample) = 
activity in the presence of test compound. The 
results are expressed as mean ± SEM (n = 3). 
Minimum inhibitory concentration (MIC) was 
measured with suitable dilutions (5 - 30 µg/well) 
and the results were analyzed using EZ-Fit 




Lipoxygenase activity was assayed using the 
methods as described previously [17,18], with 
slight modifications. A total volume of 200 μL 
assay mixture contained 150 μL sodium 
phosphate buffer (100 mM, pH 8.0), 10 μL test 
compound and 15 μL purified lipoxygenase 
(Sigma, USA). The contents were mixed and pre-
read at 234 nm and pre-incubated for 10 min at 
25 oC. Reaction was initiated by the addition of 
25 μL substrate solution and the change in 
absorbance was read after 6 min at 234 nm. 
Synergy HT (BioTek, USA) 96-well plate reader 
was used in all experiments. All reactions were 
carried out in triplicates. Positive and negative 
controls were included in the assay. BaicaleinR 
(0.5 mM well-1) was used as a positive control. 
Percentage inhibition and IC50 values were 
calculated as in Eq 2. 
 
Inhibition (%) = {(C – T)/C}100 …………… (2)                                
 
where C (i.e., control) = total enzyme activity 
without inhibitor, and T (i.e., test sample) = 
activity in the presence of test compound. IC50 
values (concentration at which enzyme inhibition 
is 50 %) were calculated using EZ-Fit Enzyme 
Kinetics Software (Perrella Scientific Inc. 
Amherst, USA). 
 
Statistical analysis  
 
All the measurements were done in triplicate and 
statistical analysis was performed using 
Microsoft Excel 2010. Results are presented as 




Target compounds were synthesized (Table 1) 
by following a series of reactions as described in 
experimental section and shown in Scheme-1. All 
the molecules were characterized by spectral 
data of IR, 1H-NMR, 13C-NMR and EIMS. 
 
5-[1-[(4-Chlorophenyl) sulfonyl]-3-piperidinyl]-
1, 3, 4-oxadiazole-2-thiol (Compound 3) 
 
White amorphous solid; Yield: 85 %; M.P. 145 - 
146 °C; Molecular formula: C13H14ClN3O3S2; 
Molecular Mass: 359 gmol-1; IR (KBr, cm-1) vmax: 
3033 (Ar-H), 2252 (S-H stretching), 1591 (C=N 
stretching), 1524 (Ar C=C stretching), 1327 (-SO2 
stretching); 1H-NMR (CDCl3, 300 MHz): δ 7.70 
(d, J = 8.4 Hz, 2H, H-2" & H-6"), 7.52 (d, J = 8.7 
Hz, 2H, H-3" & H-5"), 3.90 (dd, J = 11.7, 3.6 Hz, 
1H, He-2'), 3.65 (br.d, J = 11.7 Hz, 1H, Ha-2'), 
3.10-3.02 (m, 1H, H-3'), 2.65 (br.t, J = 9.9 Hz, 
1H, He-6'), 2.49 (td, J = 11.4, 3.0 Hz, 1H, Ha-6'), 
2.10-2.06 (m, 1H, Ha-5'), 1.90-1.82 (m, 1H, Ha-
4'), 1.81-1.70 (m, 1H, He-5'), 1.69-1.58 (m, 1H, 
He-4'); 13C-NMR (CDCl3, 100 MHz, δ/ppm): 178.4 
(C-2), 163.6 (C-5), 139.7 (C-1"), 134.6 (C-4"), 
129.5 (C-2" & C-6"), 128.9 (C-3" & C-5"), 47.5 
(C-2'), 46.1 (C-6'), 33.7 (C-3'), 26.5 (C-4'), 23.5 
(C-5'); EIMS (m/z): 359 [M]+, 300 
[C12H13ClN2O3S]•+, 284 [C12H13ClN2O2S]•+, 286 
[C12H13ClNO3S]+, 258 [C11H13ClNO2S]+, 175 
[C6H4ClO2S]+, 111 [C6H4Cl]+. 
 
5-{1-[(4-Chlorophenyl) sulfonyl]-3-piperidinyl} 
-1, 3, 4-oxadiazol-2-yl ethyl sulfide 
(Compound 5a) 
 
White solid; Yield: 76 %; M.P. 97 - 99 °C; 
Molecular formula: C15H18ClN3O3S2; Molecular 
Mass: 387 gmol-1; IR (KBr, cm-1) vmax: 3025 (Ar-
H), 1585 (C=N stretching), 1534 (Ar C=C 
stretching), 1321 (-SO2 stretching); 1H-NMR 
(CDCl3, 300 MHz): δ 7.65 (d, J = 8.4 Hz, 2H, H-
2" & H-6"), 7.49 (d, J = 8.7 Hz, 2H, H-3" & H-5"), 
3.91 (dd, J = 8.7, 3.6 Hz, 1H, He-2'), 3.63 (br.d, J 
= 11.7 Hz, 1H, Ha-2'), 3.21 (q, J = 7.2 Hz, 2H, H-
1"'), 3.08-3.02 (m, 1H, H-3'), 2.68 (br.t, J = 9.9 
Hz, 1H, He-6'), 2.47 (td, J = 11.4, 3.0 Hz, 1H, Ha-
6'), 2.07-2.01 (m, 1H, Ha-5'), 1.87-1.81 (m, 1H, 
Ha-4'), 1.78-1.70 (m, 1H, He-5'), 1.68-1.58 (m, 
1H, He-4'), 1.43 (t, J = 7.2 Hz, 3H, H-2"'); EIMS 
(m/z): 387 [M]+, 359 [C13H14ClN3O3S2]•+, 284 
[C12H13ClN2O2S]•+, 286 [C12H13ClNO3S]+, 258 
[C11H13ClNO2S]+, 212 [M-C6H4ClSO4]+, 175 
[C6H4ClO2S]+, 111 [C6H4Cl]+. 
 
5-{1-[(4-Chlorophenyl) sulfonyl]-3-piperidinyl} 
-1, 3, 4-oxadiazol-2-yl propyl sulfide 
(Compound 5b) 
 
Grey solid; Yield: 73 %; M.P. 102 - 104 °C; 
Molecular formula: C16H20ClN3O3S2; Molecular 
Mass: 401 gmol-1; IR (KBr, cm-1) vmax: 3027 (Ar-
H), 1589 (C=N stretching), 1537 (Ar C=C 
stretching), 1324 (-SO2 stretching); 1H-NMR 
(CDCl3, 400 MHz): δ 7.70 (d, J = 8.4 Hz, 2H, H-
2" & H-6"), 7.50 (d, J = 8.4 Hz, 2H, H-3" & H-5"), 
3.99 (dd, J = 11.6, 3.2 Hz, 1H, He-2'), 3.71 (br.d, 
J = 11.6 Hz, 1H, Ha-2'), 3.20 (t, J = 6.8 Hz, 2H, 
H-1"'), 3.18-3.16 (m, 3H, H-3'merged with propyl 
signals), 2.62 (br.t, J = 11.2 Hz, 1H, He-6'), 2.44 
(td, J = 11.6, 2.8 Hz, 1H, Ha-6'), 2.15-2.10 (m, 
1H, He-5'), 1.86-1.83 (m, 3H, Ha-5' & H-4'), 1.80 
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(sext, J = 7.2 Hz, 2H, H-2"'), 1.03 (t, J = 7.2 Hz, 
3H, H-3"'); EIMS (m/z): 401 [M]+, 359 
[C13H14ClN3O3S2]•+, 284 [C12H13ClN2O2S]•+, 286 
[C12H13ClNO3S]+, 258 [C11H13ClNO2S]+, 226 [M-
C6H4ClSO4]+, 175 [C6H4ClO2S]+, 111 [C6H4Cl]+. 
 
5-{1-[(4-Chlorophenyl) sulfonyl]-3-piperidinyl} 
-1, 3, 4-oxadiazol-2-yl allyl sulfide (Compound 
5c) 
 
Greyish white solid; Yield: 79 %; M.P. 92 - 94 °C; 
Molecular formula: C16H18ClN3O3S2; Molecular 
Mass: 399 gmol-1; IR (KBr, cm-1) vmax: 3027 (Ar-
H), 1582 (C=N stretching), 1531 (Ar C=C 
stretching), 1319 (-SO2 stretching); 1H-NMR 
(CDCl3, 300 MHz): δ 7.67 (d, J = 8.4 Hz, 2H, H-
2" & H-6"), 7.50 (d, J = 8.4 Hz, 2H, H-3" & H-5"), 
5.99-5.90 (m, 1H, H-2"'), 5.29 (dd, J = 16.8, 0.9 
Hz, 1H, H-3a"'), 3.87 (dd, J = 8.7, 3.6 Hz, 1H, He-
2'), 3.80 (d, J = 7.2 Hz, 2H, H-1"'), 3.61 (br.d, J = 
11.7 Hz, 1H, Ha-2'), 3.09-3.01 (m, 1H, H-3'), 2.66 
(br.t, J = 9.9 Hz, 1H, He-6'), 2.45 (td, J = 11.4, 3.0 
Hz, 1H, Ha-6'), 2.08-2.04 (m, 1H, Ha-5'), 1.89-
1.80 (m, 1H, Ha-4'), 1.79-1.71 (m, 1H, He-5'), 
1.67-1.59 (m, 1H, He-4'); EIMS (m/z): 399 [M]+, 
359 [C13H14ClN3O3S2]•+, 300 [C12H13ClN2O3S]•+, 
284 [C12H13ClN2O2S]•+, 286 [C12H13ClNO3S]+, 
258 [C11H13ClNO2S]+, 224 [M-C6H4ClSO4]+, 175 
[C6H4ClO2S]+, 111 [C6H4Cl]+, 41 [C3H5]+. 
 
5-{1-[(4-Chlorophenyl) sulfonyl] -3-
piperid`inyl}-1, 3, 4-oxadiazol-2-yl butyl 
sulfide (Compound 5d) 
 
Greyish white solid; Yield: 79 %; M.P. 95 - 97 °C; 
Molecular formula: C17H22ClN3O3S2; Molecular 
Mass: 415 gmol-1; IR (KBr, cm-1) vmax: 3016 (Ar-
H), 1588 (C=N stretching), 1543 (Ar C=C 
stretching), 1329 (-SO2 stretching); 1H-NMR 
(CDCl3, 300 MHz): δ 7.68 (d, J = 8.4 Hz, 2H, H-
2" & H-6"), 7.48 (d, J = 8.4 Hz, 2H, H-3" & H-5"), 
3.88 (dd, J = 8.7, 3.6 Hz, 1H, He-2'), 3.64 (br.d, J 
= 11.7 Hz, 1H, Ha-2'), 3.19 (t, J = 7.8 Hz, 2H, H-
1"'), 3.09-3.04 (m, 1H, H-3'), 2.67 (br.t, J = 10.2 
Hz, 1H, He-6'), 2.51 (td, J = 11.4, 3.0 Hz, 1H, Ha-
6'), 2.13-2.08 (m, 1H, Ha-5'), 1.93-1.87 (m, 1H, 
Ha-4'), 1.85-1.81 (m, 1H, He-5'), 1.78 (quint, J = 
7.8 Hz, 2H, H-2"'), 1.69-1.55 (m, 1H, He-4'), 1.45 
(sext, J = 7.8 Hz, 2H, H-3"'), 0.92 (t, J = 7.8 Hz, 
3H, H-4"'); EIMS (m/z): 415 [M]+, 359 
[C13H14ClN3O3S2]•+, 284 [C12H13ClN2O2S]•+, 286 
[C12H13ClNO3S]+, 258 [C11H13ClNO2S]+, 240 [M-
C6H4ClSO4]+, 175 [C6H4ClO2S]+, 111 [C6H4Cl]+. 
 
5-{1-[(4-Chlorophenyl) sulfonyl]-3-piperidinyl} 
-1, 3, 4-oxadiazol-2-yl pentyl sulfide 
(Compound 5e) 
 
White solid; Yield: 82 %; M.P. 126 - 128 °C; 
Molecular formula: C18H24ClN3O3S2; Molecular 
Mass: 429 gmol-1; IR (KBr, cm-1) vmax: 3018 (Ar-
H), 1584 (C=N stretching), 1543 (Ar C=C 
stretching), 1331 (-SO2 stretching); 1H-NMR 
(CDCl3, 300 MHz): δ 7.66 (d, J = 8.4 Hz, 2H, H-
2" & H-6"), 7.47 (d, J = 8.4 Hz, 2H, H-3" & H-5"), 
3.89 (dd, J = 8.7, 3.6 Hz, 1H, He-2'), 3.63 (br.d, J 
= 11.7 Hz, 1H, Ha-2'), 3.18 (t, J = 7.8 Hz, 2H, H-
1"'), 3.12-3.04 (m, 1H, H-3'), 2.67 (br.t, J = 10.2 
Hz, 1H, He-6'), 2.51 (td, J = 11.4, 3.0 Hz, 1H, Ha-
6'), 2.10-2.05 (m, 1H, Ha-5'), 1.93-1.85 (m, 1H, 
Ha-4'), 1.83-1.79 (m, 1H, He-5'), 1.76 (quint, J = 
7.8 Hz, 2H, H-2"'), 1.74-1.60 (m, 1H, He-4'), 1.41-
1.29 (m, 4H, H-3"' & H-4"'), 0.88 (t, J = 7.8 Hz, 
3H, H-5"'); EIMS (m/z): 429 [M]+, 359 
[C13H14ClN3O3S2]•+, 284 [C12H13ClN2O2S]•+, 286 
[C12H13ClNO3S]+, 258 [C11H13ClNO2S]+, 254 [M-
C6H4ClSO4]+, 175 [C6H4ClO2S]+, 111 [C6H4Cl]+. 
 
5-{1-[(4-Chlorophenyl) sulfonyl] -3-
piperidinyl}-1, 3, 4-oxadiazol-2-yl heptyl 
sulfide (Compound 5f) 
 
White solid; Yield: 80 %; M.P. 71 - 73 °C; 
Molecular formula: C20H28ClN3O3S2; Molecular 
Mass: 457 gmol-1; IR (KBr, cm-1) vmax: 3013 (Ar-
H), 1578 (C=N stretching), 1547 (Ar C=C 
stretching), 1337 (-SO2 stretching); 1H-NMR 
(CDCl3, 300 MHz): δ 7.70 (d, J = 8.4 Hz, 2H, H-
2" & H-6"), 7.51 (d, J = 8.4 Hz, 2H, H-3" & H-5"), 
3.99 (dd, J = 11.4, 3.3 Hz, 1H, He-2'), 3.72 (br.d, 
J = 11.4 Hz, 1H, Ha-2'), 3.22 (t, J = 7.2 Hz, 2H, 
H-1"'), 3.16-3.13 (m, 1H, H-3'), 2.61 (br.t, J = 
11.7 Hz, 1H, He-6'), 2.41 (td, J = 11.4, 2.7 Hz, 
1H, Ha-6'), 2.17-2.11 (m, 1H, He-5'), 1.90-1.71 
(m, 3H, Ha-5' & H-4'), 1.57-1.26 (m, 10H, H-2"' to 
H-6"'), 0.84 (t, J = 6.9 Hz, 3H, H-7"'); EIMS (m/z): 
457 [M]+, 359 [C13H14ClN3O3S2]•+, 284 
[C12H13ClN2O2S]•+, 286 [C12H13ClNO3S]+, 258 
[C11H13ClNO2S]+, 282 [M-C6H4ClSO4]+, 175 




-1, 3, 4-oxadiazol-2-yl octyl sulfide 
(Compound 5g) 
 
Greyish white solid; Yield: 77 %; M.P. 76 - 78 °C; 
Molecular formula: C21H30ClN3O3S2; Molecular 
Mass: 471 gmol-1; IR (KBr, cm-1) vmax: 3015 (Ar-
H), 1576 (C=N stretching), 1547 (Ar C=C 
stretching), 1338 (-SO2 stretching); 1H-NMR 
(CDCl3, 300 MHz): δ 7.67 (d, J = 8.4 Hz, 2H, H-
2" & H-6"), 7.52 (d, J = 8.4 Hz, 2H, H-3" & H-5"), 
3.87 (dd, J = 8.7, 3.6 Hz, 1H, He-2'), 3.64 (br.d, J 
= 11.7 Hz, 1H, Ha-2'), 3.18 (t, J = 7.8 Hz, 2H, H-
1"'), 3.10-3.02 (m, 1H, H-3'), 2.69 (br.t, J = 10.2 
Hz, 1H, He-6'), 2.53 (td, J = 11.4, 3.0 Hz, 1H, Ha-
6'), 2.13-2.09 (m, 1H, Ha-5'), 1.91-1.84 (m, 1H, 
Ha-4'), 1.82-1.79 (m, 1H, He-5'), 1.74 (qui, J = 7.8 
Hz, 2H, H-2"'), 1.70-1.59 (m, 1H, He-4'),1.41-1.24 
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(m, 10H, H-3"' to H-7"'), 0.85 (t, J = 6.9 Hz, 3H, 
H-8"'); EIMS (m/z): 471 [M]+, 359 
[C13H14ClN3O3S2]•+, 284 [C12H13ClN2O2S]•+, 286 
[C12H13ClNO3S]+, 258 [C11H13ClNO2S]+, 296 [M-
C6H4ClSO4]+, 175 [C6H4ClO2S]+, 113 [C8H17]+, 




The lipoxygenase inhibitory and antimicrobial 
activities of the compounds are shown in Tables 
2 and 3, respectively, while their MIC values are 
shown in Table 4. Compounds 5a, 5e, 5f and 5g 
showed very strong lipoxygenase inhibitory 
potential with 5e having % inhibition comparable 
to that of the standard, BaicaleinR. 
 
Results for antimicrobial activities revealed that  
although none of the compounds exhibited % 
inhibition comparable to the standard drug 
Ciprofloxacin® most of them had good % 
inhibition values with some (5a, 5b 5d and 5e) 
having 70 % and above with respect to S. typhi, 
E. coli and B. subtilis. 
 
Compound 5b consistently exhibited the lowest 
MIC values (relative to the other compounds) for 
all the bacterial strains used. The MIC values of 
5b were closest to those of the standard drug, 
Ciprofloxacin® when compared with MIC values 
for 5a, 5c 5d,  5e 5f and 5g (Table 4). 
 
Table 2: Lipoxygenase inhibitory activities of the compounds 
 
Compound Conc. Inhibition (%) IC50 (µM/L) 
5a 0.5 70.26 ± 0.98 127.41 ± 0.13 
5b 0.5 42.39 ± 1.65 >500 
5c 0.5 58.41 ± 0.43 265.2 ± 0.34 
5d 0.5 46.24 ± 0.92 >500 
5e 0.5 94.71 ± 0.45 20.72 ± 0.34 
5f 0.5 78.09 ± 0.56 201.31 ± 1.67 
5g 0.5 81.41 ± 0.98 204.21 ± 1.56 
Baicalein 0.5 93.79 ± 1.27 22.41 ± 1.30 
Values are Mean ± S.E.M 
 




Gram negative bacterial strains Gram positive bacterial strains 
S. typhi (-) E. coli (-) P. aeruginosa (-) B. subtilis (+) S. aureus(+) 
5a 71.61 ± 1.06 70.27 ± 2.55 68.85 ± 2.85 40.80 ± 5.00 63.47 ± 2.74 
5b 78.32 ± 0.41 62.04 ± 2.78 69.49 ± 0.41 63.38 ± 1.97 59.70 ± 3.70 
5c 64.22 ± 2.11 65.82 ± 1.45 61.25 ± 1.95 35.75 ± 4.85 65.47 ± 5.00 
5d 74.27 ± 1.36 64.31 ± 2.55 52.24 ± 2.14 71.87 ± 3.48 56.20 ± 0.60 
5e 76.95 ± 1.59 61.48 ± 0.83 67.45 ± 1.12 74.80 ± 2.07 60.90 ± 1.70 
5f 55.32 ± 0.68 48.43 ± 4.26 48.16 ± 5.00 53.89 ± 3.99 50.35 ± 1.65 
5g 68.09 ± 1.18 49.26 ± 1.19 52.76 ± 0.31 68.48 ± 0.71 52.65 ± 1.55 
Ciprofloxacin 91.79 ± 1.45 90.87 ± 0.56 92.13 ± 0.97 91.18 ± 1.22 90.45 ± 2.98 








Gram negative bacterial strains Gram positive bacterial strains 
S. typhi (-) E.coli (-) P. aeruginosa (-) B.subtilis (+) S. aureus(+) 
5a 13.09 ± 1.90 12.95 ± 2.00 12.67 ± 1.14 - 16.92 ± 0.98 
5b 8.18 ± 2.00 10.60 ± 1.83 10.84 ± 3.00 9.81 ± 1.86 11.73 ± 5.00 
5c 13.40 ± 2.50 12.64 ± 1.87 15.38 ± 2.50 - 16.22 ± 1.20 
5d 9.50 ± 1.03 12.72 ± 3.56 15.08 ± 1.50 9.25 ± 3.29 12.79 ± 1.42 
5e 8.24 ± 3.36 14.68 ± 0.58 13.68 ± 2.92 8.55 ± 3.21 11.99 ± 2.84 
5f 14.84 ± 0.69 - - 13.62 ± 3.50 15.39 ± 1.41 
5g 9.06 ± 1.26 - 18.37 ± 1.92 10.51 ± 2.00 16.12 ± 3.11 
Ciprofloxacin 7.15 ± 1.29 7.90 ± 1.87 8.21 ± 1.21 7.12 ± 2.11 8.00 ± 2.98 
Results are presented as mean ± SEM 
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The IR spectra of Compound 5b revealed the 
presence of C=N at 1589 cm-1, aromatic C=C 
double bond was confirmed by bands at 1537 
cm-1 and presence of sulfonyl group at about 
1324 cm-1. 1H-NMR recorded at 400 MHz using 
CDCl3 as solvent gave characteristic two 
doublets at 7.70 and 7.50 ppm for 4-chlorophenyl 
sulfonyl group while signals for piperidine ring 
have a broad range of chemical shift value 
varying for each axial and equatorial proton.  
 
Signals around 3.99ppm and 3.71ppm were to 
equatorial and axial proton of second position of 
the piperidine ring relatively downfield due to the 
adjacent electronegative nitrogen atom while 
proton of third position appeared as multiplet in 
range of 3.18 - 3.16 as a result of neighboring 
two methylene groups. Signals around 2.62 and 
2.44 belong to equatorial and axial proton of sixth 
position of piperidine ring. Four protons of fourth 
and fifth positions exhibited chemical shift at 
about 2.15 - 2.10 and 1.86 - 1.83 for equatorial 
and axial protons respectively. The propyl 
substituent on sulfur of 1, 3, 4-oxadiazole-2-thiol 
appeared in aliphatic region and was confirmed 
by two triplets, one relatively downfield at δ 
(ppm) 3.20 (t, J = 6.8 Hz, 2H, H-1"') due to 
electronegative sulfur atom. The other triplet 
methyl group appeared in upfield region at δ 
(ppm) 1.03 (t, J = 7.2 Hz, 3H, H-3"') while the 
central methylene appeared as sextet at δ (ppm) 
1.80 (sext, J = 7.2 Hz, 2H, H-2"'). The 
characteristic peaks at m/z 286 and 284 
corresponded to ({1-[(4-chlorophenyl) sulfonyl]-3-
piperidinyl} methylidyne) oxonium and 1-[(4-
chlorophenyl) sulfonyl]-3-piperidine cyanide 
cationic fragments respectively. Base peak 
appeared at m/z 175 corresponding to 4-
chlorophenyl sulfonylcation and the molecular ion 
peak was at m/z 401. The structures of all the 
other compounds were arrived at on the basis of 
these spectral information. 
 
Compounds 5e, 5g and 5f exhibited% inhibition 
values 94.71 ± 0.45, 81.41 ± 0.98 and 78.09 ± 
0.56, respectively, compared to standard 
Baicalein with % inhibition of 93.79 ± 1.27. 
Compound 5e exhibited excellent IC50 value 
20.72 ± 0.34 probably due to n-pentyl group 
substitution at 2-thiol position of oxadiazole ring 
which provides the molecule a more favorable 
geometry that probably facilitates its binding to 
active site of the enzyme, as compared to 
BaicaleinR with IC50 of 22.41 ± 1.30. 
 
The different compounds showed different 
activities against the different bacterial strains. 
Some showed good % inhibition but their MIC 
values were not so appreciable. Compounds 5a, 
5b, 5d,5e and 5g gave good % inhibition values 
against S. typhi bacterial strain but only 
compounds 5b,5d, 5e and 5g gave good MIC 
values (8.18 ± 2.00, 9.50 ± 1.03, 8.24 ± 3.36 and 
9.06 ± 1.26, respectively). This is most probably 
due to aliphatic straight chain substitutions, as 
compared to standard CiprofloxacinR 7.15 ± 1.29. 
 
The compounds 5a – 5g are S-substituted alkyl 
derivatives of 1, 3, 4 oxadiazole. The anti-
microbial and anti-inflammatory properties of 
these compounds seen in this study are in 
agreement with results reported by other studies 
involving anti-microbial and anti-inflammatory 
potential of other synthetic 1, 3, 4- oxadiazole 
derivatives. Some novel 1, 3, 4- oxadiazole 
derivatives have been shown to exhibit 
antimicrobial activities against S. aureus, B. 
subtilis, E. coli and Pseudomonas [19]. In 
addition, potent antimicrobial and anti-
inflammatory derivatives of 1, 3, 4 oxadiazole 
have been chemically synthesized by 
condensation of 4-methoxybenzo hydride with 
different aromatic acids [20]. New antimicrobial 
derivative of 1 3, 4-oxodiazole with 5 – chloro – 2 
– methoxyphenyl moiety have also been reported 




Our results indicate that, of the seven derivatives 
synthesized and studied, compound 5e shows 
the best lipoxygenase inhibitory activity, probably 
due to the effect of the n-pentyl chain on its 
orientation, while compound 5b was the most 
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